Ionis Pharmaceuticals

Biogen opts in for Ionis' ALS candidate, plans pivotal trial
Biogen opts in for Ionis' ALS candidate, plans pivotal trial
BioCentury
BIIB067
Biogen
Ionis Pharmaceuticals
ALS
Flag link:
Ionis, Akcea succeed in heart drug trial, setting up Novartis decision
Ionis, Akcea succeed in heart drug trial, setting up Novartis decision
Biopharma Dive
Akcea Therapeutics
Ionis Pharmaceuticals
clinical trials
Novartis
AKCEA-APO(a)-Lrx
Flag link:
AstraZeneca and Ionis target diabetes with antisense approach to regenerating pancreatic cells
AstraZeneca and Ionis target diabetes with antisense approach to regenerating pancreatic cells
Fierce Biotech
AstraZeneca
Ionis Pharmaceuticals
type 2 diabetes
antisense
Flag link:
Roche gets option to Ionis' antisense dry AMD candidate
Roche gets option to Ionis' antisense dry AMD candidate
BioCentury
Roche
Ionis Pharmaceuticals
IONIS-FB-LRx
antisense
dry age-related macular degeneration
Flag link:
FDA clears rare disease therapy from Akcea, Ionis
FDA clears rare disease therapy from Akcea, Ionis
Biopharma Dive
FDA
Akcea
Ionis Pharmaceuticals
Tegsedi
Onpattro
Alnylam
hATTR amyloidosis
Flag link:
Ionis, Rockefeller team find peripheral blood target for Alzheimer's
Ionis, Rockefeller team find peripheral blood target for Alzheimer's
BioCentury
Ionis Pharmaceuticals
Rockefeller University
Alzheimer's disease
drug development
Flag link:
Why Biogen's Stock Ripped Higher in July
Why Biogen's Stock Ripped Higher in July
Motley Fool
Biogen
Eisai
BAN2401
Alzheimer's disease
Spinraza
Ionis Pharmaceuticals
Flag link:
Ionis-backed Dynacure bags €47M to start clinical trials
Ionis-backed Dynacure bags €47M to start clinical trials
Fierce Biotech
Dynacure
Ionis Pharmaceuticals
antisense
oligonucleotide
CNM muscular disorders
Flag link:
Why PTC Therapeutics Dropped 30.6% Today After Jumping 27.5% Yesterday
Why PTC Therapeutics Dropped 30.6% Today After Jumping 27.5% Yesterday
Motley Fool
PTC Therapeutics
risdiplam
Biogen
Ionis Pharmaceuticals
spinal muscular atrophy
Sarepta Therapeutics
Translarna
Emflaza
Flag link:
FDA Advisory Committee Votes in Favor of Waylivra for Treatment of Familial Chylomicronemia Syndrome
FDA Advisory Committee Votes in Favor of Waylivra for Treatment of Familial Chylomicronemia Syndrome
CP Wire
Akcea Therapeutics
Ionis Pharmaceuticals
FDA
advisory panel
Waylivra
Volanesorsen
FCS
Flag link:
Outlook for Ionis, Akcea drug marred by safety concerns
Outlook for Ionis, Akcea drug marred by safety concerns
Biopharma Dive
Ionis Pharmaceuticals
Akcea Therapeutics
FDA
advisory panel
Volanesorsen
Flag link:
Biogen To Pay Ionis $1 Billion To Develop Brain Drugs
Biogen To Pay Ionis $1 Billion To Develop Brain Drugs
Forbes
Biogen
Ionis Pharmaceuticals
drug development
R&D
Flag link:
Ionis to get up to $300 mln from licensing deal with AstraZeneca
Ionis to get up to $300 mln from licensing deal with AstraZeneca
Yahoo/Reuters
Ionis Pharmaceuticals
AstraZeneca
fatty liver disease
Flag link:
Why Pfizer's Big Win Is Bad News for Alnylam and Ionis
Why Pfizer's Big Win Is Bad News for Alnylam and Ionis
Yahoo/Motley Fool
Pfizer
Alnylam
Ionis Pharmaceuticals
tafamidis
inotersen
Patisiran
Flag link:
Pfizer's rare heart disease drug succeeds in late-stage study
Pfizer's rare heart disease drug succeeds in late-stage study
Yahoo/Reuters
Pfizer
clinical trials
tafamidis
transthyretin cardiomyopathy
rare disease
Alnylam
Ionis Pharmaceuticals
Flag link:
Ionis Sends Nerve Drug to Spinout Akcea as Battle with Alnylam Looms
Ionis Sends Nerve Drug to Spinout Akcea as Battle with Alnylam Looms
Xconomy
Ionis Pharmaceuticals
Akcea
Alnylam
transthyretin amyloidosis
inotersen
IONIS-TTR-Lrx
Flag link:
Roche, Ionis herald a big win in early-stage Huntington’s disease trial, demonstrate disease modifying potential
Roche, Ionis herald a big win in early-stage Huntington’s disease trial, demonstrate disease modifying potential
Endpoints
Roche
Ionis Pharmaceuticals
clinical trials
Huntington's disease
IONIS-HTT Rx
Flag link:
AstraZeneca hauls kidney disease drug into the clinic after handing Ionis $30M in cash, $300M in milestones
AstraZeneca hauls kidney disease drug into the clinic after handing Ionis $30M in cash, $300M in milestones
Endpoints
AstraZeneca
kidney disease
Ionis Pharmaceuticals
AZD2373
antisense
Flag link:
Will 2018 Be Ionis Pharmaceuticals, Inc.'s Best Year Yet?
Will 2018 Be Ionis Pharmaceuticals, Inc.'s Best Year Yet?
Motley Fool
Ionis Pharmaceuticals
SMA
Spinraza
Flag link:
Biogen, Ionis looking for new SMA drugs following Spinraza's success
Biogen, Ionis looking for new SMA drugs following Spinraza's success
BioPharma Dive
Biogen
Ionis Pharmaceuticals
SMA
Spinraza
Flag link:

Pages